Ascelia Pharma AB

OSTO:ACE (Sweden)  
kr 11.04 (+4.94%) Jun 3
At Loss
P/B:
5.93
Market Cap:
kr 372.69M ($ 35.60M)
Enterprise V:
kr 364.95M ($ 34.86M)
Volume:
269.24K
Avg Vol (2M):
330.13K
Also Trade In:
Volume:
269.24K
At Loss
Avg Vol (2M):
330.13K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Ascelia Pharma AB ( ) from 2019 to Jun 04 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Ascelia Pharma AB stock (OSTO:ACE) PE ratio as of Jun 04 2024 is 0. More Details

Ascelia Pharma AB (OSTO:ACE) PE Ratio (TTM) Chart

To

Ascelia Pharma AB (OSTO:ACE) PE Ratio (TTM) Historical Data

Total 1259
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Ascelia Pharma AB PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-04 At Loss 2024-03-27 At Loss
2024-06-03 At Loss 2024-03-26 At Loss
2024-05-31 At Loss 2024-03-25 At Loss
2024-05-30 At Loss 2024-03-22 At Loss
2024-05-29 At Loss 2024-03-21 At Loss
2024-05-28 At Loss 2024-03-20 At Loss
2024-05-27 At Loss 2024-03-19 At Loss
2024-05-24 At Loss 2024-03-18 At Loss
2024-05-23 At Loss 2024-03-15 At Loss
2024-05-22 At Loss 2024-03-14 At Loss
2024-05-21 At Loss 2024-03-13 At Loss
2024-05-20 At Loss 2024-03-12 At Loss
2024-05-17 At Loss 2024-03-11 At Loss
2024-05-16 At Loss 2024-03-08 At Loss
2024-05-15 At Loss 2024-03-07 At Loss
2024-05-14 At Loss 2024-03-06 At Loss
2024-05-13 At Loss 2024-03-05 At Loss
2024-05-10 At Loss 2024-03-04 At Loss
2024-05-08 At Loss 2024-03-01 At Loss
2024-05-07 At Loss 2024-02-29 At Loss
2024-05-06 At Loss 2024-02-28 At Loss
2024-05-03 At Loss 2024-02-27 At Loss
2024-05-02 At Loss 2024-02-26 At Loss
2024-04-30 At Loss 2024-02-23 At Loss
2024-04-29 At Loss 2024-02-22 At Loss
2024-04-26 At Loss 2024-02-21 At Loss
2024-04-25 At Loss 2024-02-20 At Loss
2024-04-24 At Loss 2024-02-19 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss
2024-04-15 At Loss 2024-02-08 At Loss
2024-04-12 At Loss 2024-02-07 At Loss
2024-04-11 At Loss 2024-02-06 At Loss
2024-04-10 At Loss 2024-02-05 At Loss
2024-04-09 At Loss 2024-02-02 At Loss
2024-04-08 At Loss 2024-02-01 At Loss
2024-04-05 At Loss 2024-01-31 At Loss
2024-04-04 At Loss 2024-01-30 At Loss
2024-04-03 At Loss 2024-01-29 At Loss
2024-04-02 At Loss 2024-01-26 At Loss
2024-03-28 At Loss 2024-01-25 At Loss

Ascelia Pharma AB (OSTO:ACE) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Ascelia Pharma AB is an oncology-dedicated drug development company located in Malmo Sweden focused on orphan oncology It develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway The company has two drug candidates Orviglance and Oncoral in clinical development.